ARTICLE | Clinical News
Optrin motexafin lutetium: Phase II
October 22, 2001 7:00 AM UTC
PCYC said that preliminary data from a 75-patient U.S. Phase II trial of Optrin completed by former partner Alcon Group showed that choroidal neovascularization (CNV) closure, a potential indicator of...